AIM
UTHR icon

Artemis Investment Management’s United Therapeutics UTHR Stock Holding History

Artemis Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,502
Closed -$1.39M – 322
2021
Q3 		$1.39M Sell
7,502
-588
-7% -$116K 0.01% 273
2021
Q2 		$1.45M Buy
+8,090
New +$1.54M 0.01% 258

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Artemis Investment Management's UTHR Position: Q4 2021 in Review

Artemis Investment Management sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 7,502 shares — an estimated $1.39M sold.

Artemis Investment Management first reported a position in UTHR in Q2 2021 and held it in 2 quarters. The position peaked at $1.45M in Q2 2021. 416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • Artemis Investment Management reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Artemis Investment Management sold 7,502 United Therapeutics shares in Q4 2021, an estimated $1.39M.
  • Artemis Investment Management first reported a position in United Therapeutics in Q2 2021 and held it in 2 quarters.
  • Artemis Investment Management's United Therapeutics position peaked at $1.45M in Q2 2021.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on Artemis Investment Management's 13F filing for Q4 2021, filed 8 Feb 2022.